Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
06 Mayo 2024 - 8:30AM
Business Wire
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome
therapeutics company, today announced that management will host a
conference call and live audio webcast on May 8, 2024 at 8:30 a.m.
ET to discuss first quarter 2024 financial results and provide
business updates.
To access the conference call, please dial 800-715-9871
(domestic) or 646-307-1963 (international) and reference the
conference ID number 5686561. To join the live webcast, please
visit the “Investors and News” section of the Seres website at
www.serestherapeutics.com.
A webcast replay will be available on the Seres website
beginning approximately two hours after the event and will be
archived for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage
company developing novel microbiome therapeutics for serious
diseases. Seres’ lead program, VOWST™, obtained U.S. FDA approval
in April 2023 as the first orally administered microbiome
therapeutic to prevent recurrence of C. difficile infection (CDI)
in adults following antibacterial treatment for recurrent CDI and
is being commercialized in collaboration with Nestlé Health
Science. Seres is evaluating SER-155 in a Phase 1b study in
patients receiving allogeneic hematopoietic stem cell
transplantation. For more information, please visit
www.serestherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240506427078/en/
Investor and Media Contact: IR@serestherapeutics.com
Seres Therapeutics (NASDAQ:MCRB)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Seres Therapeutics (NASDAQ:MCRB)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024